Frederick L. Hall
Affiliations: | University of Southern California, Los Angeles, CA, United States |
Area:
Molecular Biology, Cell BiologyGoogle:
"Frederick Hall"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Morse MA, Chawla SP, Wong TZ, et al. (2021) Tumor protein p53 mutation in archived tumor samples from a 12-year survivor of stage 4 pancreatic ductal adenocarcinoma may predict long-term survival with DeltaRex-G: A case report and literature review. Molecular and Clinical Oncology. 15: 186 |
| Chawla SP, Bruckner H, Morse MA, et al. (2019) A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer. Molecular Therapy Oncolytics. 12: 56-67 |
| Gordon EM, Chawla SP, Hall FL. (2019) Survival data following phase 1/2 studies using precision tumor-targeted gene delivery to advanced chemotherapy-resistant malignancies. Journal of Global Oncology. 5: 101-101 |
| Gordon EM, Szeto C, Ravicz JR, et al. (2019) Abstract 2556: Enhanced expression of human cyclin G1 (CCNG1) gene in metastatic cancer, a novel biomarker in development for CCNG1 inhibitor therapy Cancer Research. 79: 2556-2556 |
| Al-Shihabi A, Chawla SP, Hall FL, et al. (2018) Exploiting Oncogenic Drivers along the CCNG1 Pathway for Cancer Therapy and Gene Therapy. Molecular Therapy - Oncolytics. 11: 122-126 |
| Gordon EM, Ravicz JR, Liu S, et al. (2018) Cell cycle checkpoint control: The cyclin G1/Mdm2/p53 axis emerges as a strategic target for broad-spectrum cancer gene therapy - A review of molecular mechanisms for oncologists. Molecular and Clinical Oncology. 9: 115-134 |
| Ravicz J, Liu S, Andrali SS, et al. (2018) Differential expression of human cyclin G1 (CCNG1) in cancer: A novel biomarker in development for CCNG1 inhibitor therapy. Journal of Clinical Oncology. 36: e24315-e24315 |
| Kim S, Federman N, Gordon EM, et al. (2017) Rexin-G(®), a tumor-targeted retrovector for malignant peripheral nerve sheath tumor: A case report. Molecular and Clinical Oncology. 6: 861-865 |
| Hall FL, Chawla SP, Chawla NS, et al. (2016) Abstract 2203: Targeting monoclonal antibodies to the tumor microenvironment for cancer immunotherapy Cancer Research. 76: 2203-2203 |
| Ignacio JG, Bruckner H, Manalo RE, et al. (2011) Tumor-targeted cancer vaccination (GeneVieve Protocol): A phase I/II study of intravenous Rexin-G and Reximmune-C for chemotherapy-resistant cancers. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 2589 |